Rituximab Combined with Autologous Peripheral Blood Stem Cell Transplantation Improve Therapeutic Effects of Chemotherapy in Pediatric Patients with Burkitt's Lymphoma
Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.Journal of Tropical Pediatrics (Impact Factor: 1.26). 10/2010; 56(5):337-41. DOI: 10.1093/tropej/fmp137
We report on 2 children with Burkitt's lymphoma accompanied by extensive extranodal involvement treated with chemotherapy and Rituximab in combination with autologous peripheral blood stem cell transplantation (Auto-PBSCT) regimens. No obvious side effects could be seen during the Rituximab therapy. Both children achieved complete remission with no relapse after being followed up for 4.3 and 4 years, respectively. Our limited experience show that Rituximab in combination with chemotherapy and Auto-PBSCT might have better therapeutic effects on Burkitt's lymphoma of children and the side effects of Rituximab therapy is minimal and can be well tolerated.
- [Show abstract] [Hide abstract]
ABSTRACT: Burkitt lymphoma (BL) is an aggressive B-cell neoplasm with an extremely short doubling time that mainly affects children and young adults. Despite having several characteristic features, none is entirely specific for BL and the differential diagnosis may include diffuse large B-cell lymphoma (DLBCL), B lymphoblastic leukemia/lymphoma, and B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL. We outline a practical approach to establish a diagnosis of BL and distinguish it from other high-grade B-cell malignancies. We pay particular attention to B-cell lymphomas with features intermediate between DLBCL and BL, a new diagnostic category in the 2008 World Health Organization classification system that provides a framework for categorizing challenging cases not meeting diagnostic criteria for either “classic” BL or DLBCL.Surgical Pathology Clinics 12/2010; 3(4):1035–1059. DOI:10.1016/j.path.2010.09.010
- [Show abstract] [Hide abstract]
ABSTRACT: Background Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma with rapid proliferation. It has become evident that miRNAs are involved in hematopoietic malignancies. This study was undertaken to investigate the miRNA expression patterns of pediatric intestinal BL tissues. Methods We collected 28 BL patients and 8 reactive lymphoid hyperplasia (RLH) samples. miRNA expression profiling was performed in BL and RLH tissues to identify BL-related miRNAs,which was further analyzed by qRT-PCR and miRNA-ISH. In addition, immunohistochemistry (IHC) and western blot were used to define the protein targets of the BL-related miRNAs. Furthermore, we evaluated cell growth status by using Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay in Raji cell line, which was transected with the BL-related miRNA mimics or inhibitors. Results MiRNA expression profiling showed that miR-150 had an extremely decrease expression levels in BL patients. In both ISH and qRT-PCR analysis, BL had reduced levels of miR-150 expression compared with RLH. But there is no significant correlation of miR-150 expression and EBV status in BL. Moreover, IHC and western blotting defined that c-myb and Survivin are the protein targets of miR-150. Re-expression of miR-150 reduced proliferation of Raji cells. Conclusions Deregulation of miR-150 may be useful as a diagnostic tool in BL, based on miRNA profile screening, qRT-PCR and miRNA-ISH. miR-150 plays an important role in BL by targeting of c-Myb and Survivin.Re-expression of miR-150 reduced proliferation of Raji cells, which suggest it as a promising novel candidate for tumor treatment.Experimental and Molecular Pathology 04/2014; 96(2). DOI:10.1016/j.yexmp.2014.02.015 · 2.71 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.